The global metastatic castration-sensitive prostate cancer treatment market is showing significant development. This increase can be linked to factors such as an elevating population, escalating prevalence of prostate cancer, and developments in treatment choices. The market is moreover driven by enhanced knowledge about the disease and its treatme